Figure 3
Early response in bulky, chemoresistant lymphoma. A 33-year-old woman with CLL/SLL had a partial response lasting 10 months after initial therapy with 6 cycles of fludarabine-R and then experienced progressive disease while receiving pentostatin-cyclophosphamide-R, and continued progressive disease while receiving CHOP. (A) Baseline image reveals a dominant 12 cm left submandibular mass. She was treated with 32 mCi of 90Y-ibritumomab tiuxetan, fludarabine, 2 Gy TBI, and a matched unrelated allogeneic transplant and achieved a PR by after transplantation day 28 (B) and complete remission by day 84. The patient remains alive and disease-free 3 years after transplantation.

Early response in bulky, chemoresistant lymphoma. A 33-year-old woman with CLL/SLL had a partial response lasting 10 months after initial therapy with 6 cycles of fludarabine-R and then experienced progressive disease while receiving pentostatin-cyclophosphamide-R, and continued progressive disease while receiving CHOP. (A) Baseline image reveals a dominant 12 cm left submandibular mass. She was treated with 32 mCi of 90Y-ibritumomab tiuxetan, fludarabine, 2 Gy TBI, and a matched unrelated allogeneic transplant and achieved a PR by after transplantation day 28 (B) and complete remission by day 84. The patient remains alive and disease-free 3 years after transplantation.

Close Modal

or Create an Account

Close Modal
Close Modal